Document is current
Any future updates will be listed below
-
Authors
Tamagawa, Momona
Nagino, Ken https://orcid.org/0000-0002-0317-6074
Sung, Jaemyoung
Midorikawa-Inomata, Akie
Eguchi, Atsuko
Morooka, Yuki
Huang, Tianxiang
Nakao, Shintaro https://orcid.org/0000-0003-4200-0052
Inomata, Takenori https://orcid.org/0000-0003-3435-1055
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (25K20553, 23K16364, 24K19796, 23K18406)
Japan Agency for Medical Research and Development (24hma322004s0803)
MEXT | Japan Science and Technology Agency (JPMJFR234I)
- License Information
-
More Information
Article History
Received: 21 December 2024
Revised: 16 May 2025
Accepted: 3 June 2025
First Online: 6 June 2025
Competing interests
: KN and AMI received personal fees from InnoJin, Inc., outside of the submitted work. SN reports grants from Kowa Company. Ltd., Mitsubishi Tanabe Pharma Corporation, Alcon Japan, Ltd., Santen Pharmaceutical Co., Ltd., Machida Endoscope Co., Ltd., Wakamoto Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Senju Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Hoya Corporation, and Novartis Pharma KK, outside the submitted work. TI reports non-financial support from Lion Corporation and Sony Network Communications Inc., grants from Johnson & Johnson Vision Care, Inc., Yuimedi, Inc., ROHTO Pharmaceutical Co., Ltd., Kobayashi Pharmaceutical Co., Ltd., Kandenko Co., Ltd., and Fukoku Co., Ltd., personal fees from Santen Pharmaceutical Co., Ltd., InnoJin, Inc., and Ono Pharmaceutical Co., Ltd., outside the submitted work. The remaining authors declare no competing interests.
